City-based full service clinical research organisation (CRO) Cliantha Research has acquired US-based Inflamax Research. The deal enables Cliantha Research to conduct Phase I, II, III and IV clinical research in North America region.

Inflamax has a presence in Toronto, ON, Neptune, NJ and Newark, NJ.

Inflamax’s world renowned expertise in inflammatory disease research and patented natural allergen Environmental Exposure Chambers (EEC) will allow Cliantha to conduct Asthma, Allergy, Ophthalmology, and Tobacco research plus specialised pulmonary/respiratory therapeutic studies, according to a company statement.

"Inflamax is the leader in research in inflammatory disease with specialty in Environmental Exposure Chamber technologies. Now we can provide our sponsors with advanced clinical trial designs along with a strong, highly experienced scientific team in North America. This acquisition brings us closer to our goal of offering highly specialised trials to our sponsor," said Vijay Patel, Executive Director, Cliantha Research.

Piyush Patel, CEO of Inflamax Research, commented, "This merger brings together the best of our collective scientific research capabilities and expands our infrastructure and offerings to our clients. There are many synergies between Inflamax Research and Cliantha which will offer new and expanded opportunities to our clients."

Both firms are committed to a smooth, well planned integration of services in North America and India. The synergy of the combined companies expands service offerings and will drive growth.